Last updated date
ABOUT THIS STUDY
The purpose of this study is to estimate the relative bioavailability of the commercial
tablet with one prototype extemporaneous preparation suspension formulation, to assist with
internal decision making on formulation development.
Study Location
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
Hypercholesterolemia
Sex
Females and Males
Age
18-55 years
Inclusion Criteria
Show details
- Healthy male and/or female subjects
- Body Mass Index (BMI) of approximately 18 to 30 kg/m2
Exclusion Criteria
Show details
- Any condition possibly affecting drug absorption
- A positive urine drug screening
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
HypercholesterolemiaStudy to Assess if Internet-Based Tailored Advice Could Modify Behaviour to Improve Health
NCT00220974
- Camperdown, New South Wales
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HypercholesterolemiaBioequivalence Study Of Pediatric Appropriate Formulation
NCT00758004
- New Haven, Connecticut
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HypercholesterolemiaBioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet
NCT00917644
- Miami, Florida
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HypercholesterolemiaSingle Dose Study of PF-06815345 in Healthy Subjects
NCT02654899
- Brussels,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Bioavailability Study for New Atorvastatin Formulation | |||
Official Title ICMJE | An Open Label, Single Dose, Randomized 2-Way Crossover Study To Estimate The Relative Bioavailability Of Atorvastatin Commercial Tablet, And An Extemporaneous Preparation (EP) Suspension Formulation, In Healthy Subjects | |||
Brief Summary | The purpose of this study is to estimate the relative bioavailability of the commercial tablet with one prototype extemporaneous preparation suspension formulation, to assist with internal decision making on formulation development. | |||
Detailed Description | Estimation of Relative Bioavailability | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 4 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Crossover Assignment Masking: None (Open Label) Primary Purpose: Other | |||
Condition ICMJE | Hypercholesterolemia | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 12 | |||
Original Actual Enrollment ICMJE | Same as current | |||
Actual Study Completion Date ICMJE | March 2008 | |||
Actual Primary Completion Date | March 2008 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years to 55 Years (Adult) | |||
Accepts Healthy Volunteers ICMJE | Yes | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00844376 | |||
Other Study ID Numbers ICMJE | A2581164 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Pfizer ( Pfizer's Upjohn has merged with Mylan to form Viatris Inc. ) | |||
Study Sponsor ICMJE | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | February 2021 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |